Adherence to Gender Affirming Hormone Therapy in Transgender Adolescents and Adults: A Retrospective Cohort Study
The Journal of Clinical Endocrinology & Metabolism · 18.10.2023 · 108 (11) · e1236-e1244
DOI: 10.1210/clinem/dgad306 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 29.05.2023. Verfasst von Pranav Gupta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Endocrinology, Emory University School of Medicine, Atlanta, GA 30322, USA. Hauptthemen laut MEDLINE: Transgender Persons. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NICHD NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Context
Transgender and gender diverse (TGD) individuals often seek gender-affirming hormone therapy (GAHT). While receipt of GAHT has been associated with improved well-being, the risk of GAHT discontinuation and its reasons are not well known.
Objective
There were two main objectives: (1) To investigate the proportion of TGD individuals who discontinue therapy after an average of 4 years (maximum 19 years) since GAHT initiation; and (2) to explore reasons for GAHT discontinuation. This was a retrospective cohort study at academic centers providing care to TGD adolescents and adults. TGD individuals prescribed estradiol or testosterone between January 1, 2000, and January 1, 2019, were included. GAHT continuation was ascertained using a 2-phase process. In phase 1, Kaplan–Meier survival analyses were used to examine likelihood of GAHT discontinuation and compare discontinuation rates by age and sex assigned at birth. In phase 2, reasons for stopping GAHT were investigated by reviewing records and by contacting study participants who discontinued therapy. The main outcome measures were incidence and determinants of GAHT discontinuation.
Results
Among 385 eligible participants, 231 (60%) were assigned male at birth and 154 (40%) were assigned female at birth. Less than one-third of participants (n = 121) initiated GAHT prior to their 18th birthday, constituting the pediatric cohort (mean age 15 years), and the remaining 264 were included in the adult cohort (mean age 32 years). In phase 1, 6 participants (1.6%) discontinued GAHT during follow-up, and of those only 2 discontinued GAHT permanently (phase 2).
Conclusion
GAHT discontinuation is uncommon when therapy follows Endocrine Society guidelines. Future research should include prospective studies with long-term follow-up of individuals receiving GAHT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Endocrinology, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Department of Pediatrics, Division of Endocrinology, Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.
- Emory University School of Medicine, Atlanta, GA 30322, USA.
- Department of Dermatology, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Rollin's School of Public Health, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Department of Medicine, Division of Endocrinology, Metabolism and Lipids, Emory University School of Medicine, Atlanta, GA 30322, USA.
ORCID-Profile: Pranav Gupta, Michael Goodman, Vin Tangpricha
Förderung
- NIAMS NIH HHS
- NICHD NIH HHS
- NIA NIH HHS
- NCATS NIH HHS
- Emory University Department of Pediatrics and Children’s Healthcare of Atlanta
- National Center for Advancing Translational Sciences of the National Institutes of Health
- Patient Centered Outcome Research Institute
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Gupta, P., Patterson, B. C., Chu, L., Gold, S., Amos, S., Yeung, H., Goodman, M., & Tangpricha, V. (2023). Adherence to Gender Affirming Hormone Therapy in Transgender Adolescents and Adults: A Retrospective Cohort Study. The Journal of Clinical Endocrinology & Metabolism, 108(11), e1236-e1244. https://doi.org/10.1210/clinem/dgad306
Vancouver
Gupta P, Patterson BC, Chu L, Gold S, Amos S, Yeung H, et al. Adherence to Gender Affirming Hormone Therapy in Transgender Adolescents and Adults: A Retrospective Cohort Study. The Journal of Clinical Endocrinology & Metabolism. 2023;108(11):e1236-e1244. doi:10.1210/clinem/dgad306
BibTeX
@article{Gupta2023,
author = {Gupta, Pranav and Patterson, Briana C and Chu, Lena and Gold, Sarah and Amos, Seth and Yeung, Howa and Goodman, Michael and Tangpricha, Vin},
title = {Adherence to Gender Affirming Hormone Therapy in Transgender Adolescents and Adults: A Retrospective Cohort Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {11},
pages = {e1236--e1244},
doi = {10.1210/clinem/dgad306}
}
EUVIMED